Stockscreener 앱 받기
16.91
0.47%
-0.08
시간 외 거래:
16.91
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch + Lomb earnings up next: Can growth offset pipeline loss? - Investing.com
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Bausch + Lomb Corp (BLCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.260|Chg%:+0.090 - TradingKey
Bausch + Lomb Corporation Revenue Breakdown – MUN:S2L - TradingView
Bausch + Lomb Corp (BLCO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Investor Outlook: Bausch + Lomb Corporation (BLCO) Eyes 12% Upside Potential Amid Steady Growth - DirectorsTalk Interviews
Bausch + Lomb Corp (BLCO) Balance Sheet - TradingKey
Bausch + Lomb Corp (BLCO) Cash Flow - TradingKey
Bausch + Lomb Corp (BLCO) Income Statement - TradingKey
Bausch + Lomb Corp (BLCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.170|Chg%:+0.210 - TradingKey
Bausch + Lomb Corporation (BLCO) Gets a Hold from Wells Fargo - The Globe and Mail
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead - Yahoo Finance
Bausch + Lomb launches EyeGility preloaded IOL delivery system in US - Ophthalmology Times Europe
Bausch + Lomb launches EyeGility inserter for enVista IOLs in the US - MSN
Bausch Health Companies stock hits 52-week low at $4.56 By Investing.com - Investing.com South Africa
Bausch Health Companies stock hits 52-week low at $4.56 - Investing.com
Bausch + Lomb launches EyeGility Inserter to streamline cataract lens delivery in US - Indian Pharma Post
BHC5652799 Bond Profile — Key Metrics - TradingView
Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System - VisionMonday.com
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Nigeria
Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says - Moomoo
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S. - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing A Potential 11.54% Upside - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
Bausch + Lomb launches EyeGility IOL delivery system in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant - Ophthalmology Times Europe
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States - marketscreener.com
Bausch + Lomb launches EyeGility IOL delivery system in U.S. - Investing.com
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States - Business Wire
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21 - Moomoo
(BLCO) Equity Market Report (BLCO:CA) - Stock Traders Daily
Bausch + Lomb's BL1107 fails primary end point in Phase 2 glaucoma trial - Optometry Times
Ophthalmology Devices Market Report Released, Includes - GlobeNewswire
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others - Yahoo Finance UK
Bausch + Lomb Corporation (BLCO) Stock Analysis: Examining a Healthcare Leader with 11.68% Potential Upside - DirectorsTalk Interviews
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - BioSpace
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates - Yahoo Finance
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform - VisionMonday.com
Bausch + Lomb halts glaucoma eye drop program after trial miss - Investing.com UK
Bausch + Lomb halts glaucoma eye drop program after trial miss By Investing.com - Investing.com South Africa
2.49%
0.42%
자본화:
|
볼륨(24시간):